Skip to main content

Table 1 Demographic data

From: Perioperative patient-specific factors-based nomograms predict short-term periprosthetic bone loss after total hip arthroplasty

Variables

Prevalence or average

Age (years)

59.3 ± 10.8

Male

45.7% (195/427)

Married

94.1% (402/427)

BMI (kg/m2)

23.4 ± 3.8

Current/former smoker

39.6% (169/427)

Comorbidities

 Diabetes mellitus

17.3% (74/427)

 Hypertension

36.3% (155/427)

 Stroke

6.8% (29/427)

 Heart dysfunction

8.7% (37/427)

 Othersa

17.1% (73/427)

Diagnosis

 Femoral neck fracture

22.7% (97/427)

 Femoral head necrosis

49.6% (212/427)

 Hip osteoarthritis

17.8% (76/427)

 Developmental dysplasia of the hip

9.8% (42/427)

History of anti-osteoporosis therapy in the last year

20.4% (87/427)

Preoperative systematic BMD

 Spine (g/cm2)

0.881 ± 0.150

 Hip (g/cm2)

0.828 ± 0.181

Serum ALP (U/L)

74.9 ± 25.6

Serum calcium (mmol/L)

2.31 ± 0.12

Preoperative Harris score of the involved hip

41.7 ± 19.9

Femoral component design

 Straight stem

65.1% (278/427)

 Anatomic stem

34.9% (149/427)

  1. aindicated other comorbidities including chronic obstructive pulmonary disease, pulmonary infection, dementia, Parkinson’s disease, digestive system disorders, and chronic renal failure